Baseline Characteristics of Contemporary Trial Participants with Heart Failure and Reduced Ejection Fraction: The VICTOR Trial
European Journal of Heart Failure · 2025
DOI: 10.1002/ejhf.3598 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Heart Failure, 2025. Verfasst von Clara I Saldarriaga und 21 weiteren Autor:innen. Beteiligte Einrichtung: Cardio VID Clinic, Medellin, Colombia. Hauptthemen laut MEDLINE: Heart Failure, Stroke Volume, Aminobutyrates, Ventricular Function, Left. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Bayer AG, Wuppertal, Germany, Bayer.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Aims
To describe the baseline characteristics of the participants in the VICTOR (Vericiguat Global Study in Patients with Chronic Heart Failure; NCT05093933) trial and compare them to recent trials in patients with heart failure and reduced ejection fraction (HFrEF). Methods and results Baseline characteristics were evaluated in 6105 patients randomized to vericiguat or placebo. The mean age of the participants was 67 ± 11 years, 23.6% were women, 64.4% were White, and 10.7% were self-identified Black. Overall, 29.1% of participants were enrolled in Latin and South America, 27.8% and 18.5% in Eastern and Western Europe, 14.0% in Asia-Pacific and 10.6% in North America. The mean left ventricular ejection fraction was 30 ± 7% and 79% had New York Heart Association class II symptoms. Mean estimated glomerular filtration rate was 70.9 ± 24.0 ml/min/1.73 m2. Median N-terminal pro-B-type natriuretic peptide level was 1476 (970–2495) pg/ml and 47.5% of participants had no prior hospitalization for heart failure. Baseline therapy included 94.4% beta-blockers, 94.3% renin–angiotensin system modulation (including 56.0% on an angiotensin receptor–neprilysin inhibitor), 77.7% mineralocorticoid receptor antagonists, 59.1% sodium–glucose cotransporter 2 inhibitors, and 32.9% implantable cardioverter-defibrillators. Overall characteristics were relatively similar to other recent HFrEF trials but the VICTOR trial enrolled a higher proportion of participants receiving contemporary drug and device therapy.
Conclusion
The VICTOR trial enrolled the most optimally treated population in a phase III heart failure trial. These features will facilitate assessment of the benefit of vericiguat and elucidate the outcomes of patients on up-to-date medical therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardio VID Clinic, Medellin, Colombia.
- CVCT and Université de Lorraine, Nancy, France.
- Merck & Co., Inc., Rahway, NJ, USA.
- University of North Carolina, Chapel Hill, NC, USA.
- Colorado Prevention Center Clinical Research, Department of Medicine, University of Colorado, Aurora, CO, USA.
- Bayer AG, Basel, Switzerland.
Förderung
- Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
- Bayer AG, Wuppertal, Germany
- Bayer
Zitieren
APA
Saldarriaga, C. I., Zannad, F., McMullan, C. J., Xing, A., Gates, D., Anstrom, K. J., Bonaca, M. P., Corda, S., Ezekowitz, J. A., Lam, C. S. P., Lewis, E. F., Lindenfeld, J., Mentz, R. J., O'Connor, C., Patel, M., Ponikowski, P., Reddy, Y. N. V., Rosano, G. M. C., Senni, M., …, & Butler, J. (2025). Baseline Characteristics of Contemporary Trial Participants with Heart Failure and Reduced Ejection Fraction: The VICTOR Trial. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3598
Vancouver
Saldarriaga CI, Zannad F, McMullan CJ, Xing A, Gates D, Anstrom KJ, et al. Baseline Characteristics of Contemporary Trial Participants with Heart Failure and Reduced Ejection Fraction: The VICTOR Trial. European Journal of Heart Failure. 2025. doi:10.1002/ejhf.3598
BibTeX
@article{Saldarriaga2025,
author = {Saldarriaga, Clara I and Zannad, Faiez and McMullan, Ciaran J and Xing, Aiwen and Gates, Davis and Anstrom, Kevin J and Bonaca, Marc P and Corda, Stefano and Ezekowitz, Justin A and Lam, Carolyn S P and Lewis, Eldrin F and Lindenfeld, JoAnn and Mentz, Robert J and O'Connor, Christopher and Patel, Mahesh and Ponikowski, Piotr and Reddy, Yogesh N V and Rosano, Giuseppe M C and Senni, Michele and Udelson, James and Voors, Adriaan A and Butler, Javed},
title = {Baseline Characteristics of Contemporary Trial Participants with Heart Failure and Reduced Ejection Fraction: The VICTOR Trial},
journal = {European Journal of Heart Failure},
year = {2025},
doi = {10.1002/ejhf.3598}
}
EUVIMED